CHICAGO, IL USA (Press Release) - May 14, 2014
– Summary contains updated data not included in the abstract –
According to a large, population-based observational study of men who had a PSA-only based relapse after prostate surgery or radiation therapy, delaying androgen deprivation therapy (ADT, also known as hormone therapy) until the onset of symptoms or appearance of cancer on a scan does not substantially compromise long-term survival. The findings – relevant to roughly 60,000 U.S. men – suggest that it may be safe to postpone ADT, reducing and/or delaying treatment-related side effects and costs.
“Rising PSA levels trigger a lot of anxiety, and many men want to start treatment as soon as possible,” said lead study author Xabier Garcia-Albeniz, MD, a research associate at Harvard University School of Public Health in Boston, MA. “These findings suggest that there may be no need to rush to ADT. If our results are confirmed in randomized trials, patients could feel more comfortable waiting until they develop symptoms or signs of cancer that are seen on a scan, before initiating ADT.” The current study provides novel data on patients with so-called “PSA relapse,” where PSA levels are increased but patients have no symptoms, and there is no evidence of a tumor on a CT or bone scan. There are no standard guidelines for timing of ADT initiation in such patients.
The study analyzed national prospective registry data (CaPSURE: Cancer of the Prostate Strategic Urologic Research Endeavor, based at the University of California, San Francisco) on over 14,000 patients, 2,012 of whom had a PSA relapse after radical prostatectomy or radiation therapy with curative intention. Patients were assigned to the “immediate” strategy if they received ADT within three months of PSA relapse. They were assigned to the “deferred” strategy if they started ADT at least two years after the PSA relapse, or when they presented with metastasis, symptoms, or a short PSA doubling time.
In the current observational study, the median time from primary treatment to PSA relapse was 27 months. After a relapse, patients were followed for a median period of 41 months. The estimated five-year overall survival was similar between the two ADT timing strategies: 87.2 percent for deferred ADT vs. 85.1 percent for immediate ADT, suggesting that there was little or no survival benefit of immediate ADT initiation compared with deferred initiation. As this was an observational study, the authors cannot exclude the possibility that some unmeasured characteristics affecting survival (e.g., healthy behavior, diet, blood pressure) were different among compared groups and, despite the best possible statistical adjustment, the true difference between the compared strategies might differ from the one reported. In practice, deferred initiation could help delay ADT by two or more years for some men, according to the authors, offering men substantially better quality of life by avoiding common and often debilitating side effects ─ sexual dysfunction, osteoporosis and risk of bone fracture, hot flashes, decreased mental sharpness, fatigue, loss of muscle mass, increased cholesterol, weight gain, and depression. Some of those side effects may become more severe the longer a patient is on ADT.
This research was supported in part by the National Institutes of Health (P01-CA134294), ASISA, SEOM (Sociedad Española de Oncología Médica) and an independent educational grant from Abbott.
"Hormone therapy is one of the oldest, most common and most effective treatment approaches in prostate cancer, and these findings will influence the treatment of thousands of patients worldwide,” said Peter P. Yu, MD, FASCO, ASCO President-Elect. “This study is also a great example of how less aggressive treatment can sometimes offer patients optimal outcomes while sparing them from side effects that impair their quality of life."
Relevant Links From Cancer.Net, the oncologist-approved cancer information website from the American Society of Clinical Oncology:
Title: Immediate versus deferred initiation of androgen deprivation therapy in prostate cancer patients with PSA-only relapse.
Authors: Xabier Garcia-Albeniz, June M. Chan, Alan T Paciorek, Roger W Logan, Stacey A. Kenfield, Matthew R. Cooperberg, Peter Caroll, Miguel Hernan
Harvard School of Public Health, Boston, MA; University of California, San Francisco, San Francisco, CA; Department of Urology and Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA; Department of Urology, University of California, San Francisco, San Francisco, CA
Background: The optimal timing to start androgen deprivation therapy (ADT) in patients with rising PSA as the only sign of relapse is unknown. ASCO guidelines state “the critical issue is to determine whether there is benefit and how large it is for starting ADT while patients are asymptomatic.”
Methods: We studied 2,022 men in the Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE), a national prospective registry, staged < cT3aN0M0, treated with radical prostatectomy (RP) or radiotherapy (RT) and had a PSA relapse (> 0.2 ng/mL [RP] or three rising determinations one month apart [RT]). Exclusion criteria included ADT in the 12 months before inclusion, metastatic disease by CT scan or bone scan, and symptoms. We assigned patients to the “immediate” strategy if they initiated ADT within 3 months (grace period) of PSA relapse and to the “deferred” strategy if they initiated ADT 2 or more years after PSA relapse or when they presented with metastasis, symptoms or a short PSA doubling time. We did not allow a treatment other than ADT for PSA relapse (e.g., rescue RT). We censored patients when they deviated from the assigned strategy and adjusted for this censoring via inverse probability weighting where the weights are a function of time-varying confounders: PSA, Karnofsky, weight loss, and bone pain.
Results: Of the 2,022 patients analyzed, median age was 69 (range 63 to 74) years, 33.8% had a Gleason score >7, 31.8% received radiotherapy as primary treatment, and median time from primary treatment to PSA relapse was 27 (range 14 to 51) months. After relapse, patients were followed a median of 53.2 months. All cause mortality HR for “immediate ADT” vs. “deferred ADT” was 1.06 (95% CI: 0.59 to 1.89), corresponding to a survival difference at 5 years of -5.5% (95% CI: -15.1 % to 4.2%). The prostate-cancer specific mortality HR was 1.48 (95% CI 0.69-3.16), corresponding to a 5-year survival difference of -5.6% (95% CI: -12.5% to 1.3%).
Conclusions: Our study suggests little or no survival benefit of immediate ADT initiation for immediate ADT initiation compared with deferred ADT initiation (at clinical progression or at least two years after PSA relapse) among prostate cancer patients with PSA-only relapse.
Disclosures: Nothing to disclose.
Research Funding Source: NIH, UCSF CaPSURE Program (funded in part by an educational grant from Abbott Laboratories), ASISA, Spanish Society of Medical Oncology
American Society of Clinical Oncology (ASCO)
[ PRESS RELEASE ]